SUPERNUS PHARMACEUTICALS, INC. (SUPN) Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
Sector: Pharmaceutical Preparations
Industry: Drug Manufacturers - Specialty & Generic
Trading halted (T12) Halted since Oct 31, 2026. Last trade $41.92. The price shown is frozen at the last trade before the halt and resumes updating when trading resumes.
Supernus Pharmaceuticals, Inc. NASDAQ:SUPN Healthcare · Drug Manufacturers - Specialty & Generic
Mkt Cap $2.44B
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release ● Major ⚠ 3
Supernus Announces Third Quarter 2026 Financial Results
Supernus posted record Q3 2026 total revenues of $226.8 million, up 18% year-over-year, driven by 29% growth across its four growth products.
The company swung to GAAP operating earnings of $21.2 million from a $60.2 million loss a year ago, with diluted EPS of $0.35 versus $(0.80). ONAPGO net sales surged 151% to $17.1 million and received seven years of FDA orphan-drug exclusivity; Qelbree grew 12% to $90.8 million and ZURZUVAE collaboration revenue more than doubled to $41.7 million.
Management raised stand-alone FY26 guidance to $875-$900 million in revenue and $160-$180 million in adjusted operating earnings.
The all-stock merger with Indivior, approved by both shareholder bases on October 15, is expected to close November 2, 2026, creating a combined CNS company targeting $125 million in annual cost synergies; the combined Supernus, Inc. will trade as SUPN from November 3.
• 3d ago AI analysis › Press Release
Updated Effective Date: Huron Consulting Group Set to Join S&P SmallCap 600
Huron Consulting Group will join the S&P SmallCap 600 before the open on Tuesday, November 3, one day later than the originally announced November 2 effective date.
S&P DJI revised the date due to a special dividend ex-date announcement tied to Indivior Pharmaceuticals' pending acquisition of Supernus Pharmaceuticals, which frees HURN's index slot.
Index inclusion typically triggers passive-fund buying of HURN shares ahead of the effective date.
• 4d ago AI analysis › Press Release
Chloe Kim Is Changing the Conversation Around ADHD in Women with Qelbree® for ‘Ms. Represented’ Campaign
Supernus Pharmaceuticals expanded its 'Ms. Represented' ADHD awareness campaign with Olympic snowboarder Chloe Kim, a paid spokesperson for Qelbree who was diagnosed with ADHD as an adult.
Qelbree is the #1 prescribed branded non-stimulant ADHD medication as of May 2026, with approximately 3 million prescriptions filled since its 2021 launch.
The campaign targets women, a segment where more than 60% of diagnosed U.S. women first received an ADHD diagnosis in adulthood, supporting continued commercial growth for Supernus's lead ADHD franchise.
• 4d ago AI analysis › Press Release ⚠ 2
Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)
Supernus said the FDA recognized seven years of orphan-drug exclusivity for ONAPGO (apomorphine HCl), the first and only subcutaneous apomorphine infusion device for motor fluctuations in advanced Parkinson's disease.
The exclusivity period began on February 3, 2025, the date of FDA approval, providing market protection through early 2032 against competing apomorphine products.
The company also submitted an sNDA for a second ONAPGO supplier, with potential approval expected by mid-year 2027, addressing the supply issue from earlier in the year.
• 11d ago AI analysis › Press Release
Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026
Supernus Pharmaceuticals will report third quarter 2026 financial and business results after market close on Thursday, October 29, 2026.
CEO Jack Khattar and CFO Tim Dec will host a conference call and webcast at 4:30 p.m. ET the same day, with a Q&A session following prepared remarks.
This is a scheduling notice only; no financial figures or business updates are included.
• 13d ago AI analysis › Press Release
Are ITGR, BZH, SUPN Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC, an investor rights law firm, announced it is investigating Beazer Homes' proposed sale to Dream Finders Homes for $33.50 in cash per share for potential breaches of fiduciary duties.
The release is a law-firm solicitation encouraging shareholders to contact the firm at no cost on a contingency basis; it discloses no new facts about the deal itself.
The same release also names Integer Holdings (sale to KKR at $127.00/share) and Supernus Pharmaceuticals (share-for-share sale to Indivior), but the primary subject for BZH holders is only the investigation notice.
• 1mo ago AI analysis › Press Release ⚠ 1
Supernus Pharmaceuticals to Participate in September Investor Conferences
Supernus Pharmaceuticals announced that management will participate in two September investor conferences: a fireside chat at the Cantor Global Healthcare Conference on September 9, 2026 in New York, and another at the Wells Fargo Healthcare Conference on September 10, 2026 in Everett, Mass.
Live audio webcasts will be available, with archived replays accessible for 60 days on the company's website; investors seeking management meetings are directed to the conference coordinators.
The release contains no new financial, clinical, or regulatory disclosures and is a routine investor-calendar notice. A stray reference to a Jefferies Global Healthcare Conference webcast appears even though that conference is not on the listed schedule.
• 1mo ago AI analysis › Press Release
Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD
Supernus Pharmaceuticals announced a partnership with professional snowboarder Chloe Kim to promote Qelbree, its non-stimulant ADHD treatment.
The company highlighted that Qelbree has filled approximately 3 million prescriptions since its 2021 launch and is the top prescribed branded non-stimulant for ADHD as of May 2026.
As a compensated ambassador, Kim will share her experience to raise awareness of adult ADHD and encourage collaborative discussions with doctors about treatment options.
• 2mo ago AI analysis › Press Release
Are BOW, ATKR, SUPN Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC is investigating Atkore Inc. regarding its proposed sale to Prysmian S.p.A. for $95.00 per share in cash.
The firm is probing potential breaches of fiduciary duties and whether the transaction terms might limit superior competing offers for shareholders.
Shareholders are encouraged to contact the firm to discuss rights and options on a contingency fee basis with no out-of-pocket costs.
• 2mo ago AI analysis › Press Release
Are SUPN, ITGR, ATKR, LNTH Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC is investigating the board of Atkore Inc. for potential breaches of fiduciary duty regarding the proposed sale to Prysmian S.p.A. for $95.00 per share in cash.
The law firm is examining whether the transaction terms limit superior offers or provide undisclosed benefits to insiders.
Shareholders are encouraged to contact the firm to discuss their rights and options on a contingent fee basis.
• 2mo ago AI analysis › Press Release ● Critical ⚠ 2
Supernus Announces Second Quarter 2026 Financial Results
Supernus announced a definitive agreement to merge with Indivior Pharmaceuticals in an all-stock merger of equals, creating a diversified CNS biopharmaceutical company with significant scale.
Q2 total revenue rose 32% year-over-year to $219.1 million, driven by a 52% increase in combined growth product revenues including Qelbree and ZURZUVAE.
The company raised full-year 2026 revenue guidance to $860-$890 million from $840-$870 million, despite reporting a GAAP net loss due to a $54.9 million impairment charge on APOKYN.
• 2mo ago AI analysis › Press Release ● Critical ⚠ 2
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
Indivior Pharmaceuticals and Supernus Pharmaceuticals agreed to a definitive all-stock merger of equals, creating a CNS biopharmaceutical leader with $2.2 billion in combined annual revenue and expected synergies of $125 million.
Indivior shareholders will receive a one-time special cash dividend of $1.0 billion and own approximately 56.5% of the combined company, which will be named Supernus, Inc. and trade under the ticker SUPN.
The transaction is expected to close in Q4 2026, with Jack Khattar serving as CEO and the company securing a $650 million term loan to help fund the dividend.
• 2mo ago AI analysis › Press Release
Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026
Supernus Pharmaceuticals announced it will release its second quarter 2026 financial results after the market closes on Tuesday, August 4, 2026.
CEO Jack Khattar and CFO Tim Dec will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the business and financial results.
The company is a biopharmaceutical firm focused on central nervous system diseases, with a portfolio covering ADHD, Parkinson's disease, epilepsy, and migraine.
• 3mo ago AI analysis › Press Release
Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD
Supernus Pharmaceuticals is celebrating the five-year anniversary of the FDA approval of Qelbree, its non-stimulant treatment for ADHD in patients aged six and older.
Since its launch, approximately 3 million prescriptions have been filled, with over 1 million prescriptions filled in 2025 alone, indicating sustained commercial adoption.
The company highlighted key milestones including the 2022 expansion of the indication to adults and a 2025 labeling update that positioned Qelbree as the first non-stimulant ADHD treatment with specific serotonin pharmacodynamic data.
• 3mo ago AI analysis › Press Release
Supernus Expands Partnership With MERGE as AI-Powered Agency of Record
Supernus Pharmaceuticals expanded its partnership with MERGE, appointing the agency as its Agency of Record to oversee digital marketing and technology platforms.
The expanded scope now includes marketing for the ADHD treatment QELBREE and managing the full digital ecosystem for Parkinson's brands APOKYN, GOCOVRI, and ONAPGO.
Vice President of Marketing Rebecca Lannan noted that MERGE has been a trusted partner for years, demonstrating the ability to deliver tactics that contribute to the company's success.
• 4mo ago AI analysis › Press Release
Supernus Pharmaceuticals to Participate in June Investor Conferences
Supernus Pharmaceuticals announced that management will participate in two major healthcare investor conferences in June.
The company will hold a fireside chat at the Jefferies Global Healthcare Conference on June 3 in New York and attend the Goldman Sachs 47th Annual Global Healthcare Conference on June 8 in Miami.
A live webcast of the Jefferies session will be available on the company's website, with archived replays accessible for 60 days.
• 5mo ago AI analysis › Press Release
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
Supernus Pharmaceuticals announced that President and CEO Jack A. Khattar will participate in a fireside chat at the Bank of America 2026 Health Care Conference.
The presentation is scheduled for Tuesday, May 12, 2026, at 3:40 p.m. PT at the Encore Hotel in Las Vegas.
A live webcast will be available on the company's Investor Relations website, with a replay accessible for 60 days following the event.
• 5mo ago AI analysis › Press Release ● Major ⚠ 1
Supernus Announces First Quarter 2026 Financial Results
Supernus reported Q1 2026 total revenue of $207.7 million, a 39% year-over-year increase driven by a 56% jump in growth product sales to $149.1 million.
The company narrowed its net loss to $2.3 million, or $0.04 per share, from $11.8 million in the prior-year period, while adjusted operating earnings rose to $28.7 million.
Management reiterated full-year 2026 revenue guidance of $840 million to $870 million and reported a cash position of $384.2 million as of March 31.
• 5mo ago AI analysis › Press Release
Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026
Supernus Pharmaceuticals announced it will report first quarter 2026 financial results after the market closes on May 5, 2026.
President and CEO Jack Khattar and SVP and CFO Tim Dec will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results.
A live and replay webcast will be available on the company's Investor Relations website.
• 6mo ago AI analysis › 
